Summary
Marsh & McLennan Companies, Inc. (MRSH) reported solid financial performance for the six months ended June 30, 2017, with consolidated revenue increasing by 4% to $7.0 billion and net income attributable to the company rising by 12% to $1.07 billion compared to the same period in 2016. Diluted earnings per share saw a corresponding increase of 13% to $2.05. The company's operating income also grew by 8% to $1.6 billion, driven by strength in both its Risk and Insurance Services and Consulting segments. The company continued its strategic growth through acquisitions, investing $412 million in the first half of 2017 across its segments. Management also demonstrated a commitment to returning capital to shareholders through significant share repurchases totaling $400 million in the first half of the year, supported by an authorized repurchase program of approximately $2.0 billion remaining as of June 30, 2017. Despite a challenging regulatory environment with ongoing investigations in the UK and Ireland, the company's core operations show resilience and growth.
Financial Highlights
51 data points| Revenue | $3.50B |
| Operating Expenses | $2.79B |
| Operating Income | $701.00M |
| Interest Expense | $60.00M |
| Net Income | $501.00M |
| EPS (Basic) | $0.98 |
| EPS (Diluted) | $0.96 |
| Shares Outstanding (Basic) | 514.00M |
| Shares Outstanding (Diluted) | 520.00M |
Key Highlights
- 1Consolidated revenue increased by 4% to $7.0 billion for the first six months of 2017 compared to the prior year.
- 2Net income attributable to the Company grew by 12% to $1.07 billion for the first six months of 2017.
- 3Diluted earnings per share increased by 13% to $2.05 for the first six months of 2017.
- 4Operating income rose by 8% to $1.6 billion for the first six months of 2017.
- 5The company completed several strategic acquisitions, investing $412 million in the first half of 2017.
- 6Share repurchases totaled $400 million in the first six months of 2017, with $2.0 billion remaining authorization.
- 7The company is subject to ongoing regulatory investigations in the UK and Ireland concerning potential anti-competitive practices.